Metastatic Melanoma - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 675 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Melanoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Metastatic Melanoma - Pipeline Review, H1 2016', provides an overview of the Metastatic Melanoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
- The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

Introduction 7
Metastatic Melanoma Overview 8
Therapeutics Development 9
Metastatic Melanoma - Therapeutics under Development by Companies 11
Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 18
Metastatic Melanoma - Pipeline Products Glance 20
Metastatic Melanoma - Products under Development by Companies 23
Metastatic Melanoma - Products under Investigation by Universities/Institutes 31
Metastatic Melanoma - Companies Involved in Therapeutics Development 33
Metastatic Melanoma - Therapeutics Assessment 111
Drug Profiles 134
Metastatic Melanoma - Recent Pipeline Updates 434
Metastatic Melanoma - Dormant Projects 633
Metastatic Melanoma - Discontinued Products 645
Metastatic Melanoma - Product Development Milestones 647
Appendix 658

List of Tables

Number of Products under Development for Metastatic Melanoma, H1 2016 25
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2016 26
Number of Products under Development by Companies, H1 2016 28
Number of Products under Development by Companies, H1 2016 (Contd..1) 29
Number of Products under Development by Companies, H1 2016 (Contd..2) 30
Number of Products under Development by Companies, H1 2016 (Contd..3) 31
Number of Products under Development by Companies, H1 2016 (Contd..4) 32
Number of Products under Development by Companies, H1 2016 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 37
Comparative Analysis by Early Stage Development, H1 2016 38
Products under Development by Companies, H1 2016 39
Products under Development by Companies, H1 2016 (Contd..1) 40
Products under Development by Companies, H1 2016 (Contd..2) 41
Products under Development by Companies, H1 2016 (Contd..3) 42
Products under Development by Companies, H1 2016 (Contd..4) 43
Products under Development by Companies, H1 2016 (Contd..5) 44
Products under Development by Companies, H1 2016 (Contd..6) 45
Products under Development by Companies, H1 2016 (Contd..7) 46
Products under Investigation by Universities/Institutes, H1 2016 47
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 48
Metastatic Melanoma - Pipeline by AB Science SA, H1 2016 49
Metastatic Melanoma - Pipeline by AbbVie Inc., H1 2016 50
Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 51
Metastatic Melanoma - Pipeline by Affichem SA, H1 2016 52
Metastatic Melanoma - Pipeline by Agalimmune Ltd, H1 2016 53
Metastatic Melanoma - Pipeline by Agenus, Inc., H1 2016 54
Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H1 2016 55
Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H1 2016 56
Metastatic Melanoma - Pipeline by Amgen Inc., H1 2016 57
Metastatic Melanoma - Pipeline by Angimmune LLC, H1 2016 58
Metastatic Melanoma - Pipeline by Apexigen, Inc., H1 2016 59
Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 60
Metastatic Melanoma - Pipeline by Array BioPharma Inc., H1 2016 61
Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 62
Metastatic Melanoma - Pipeline by AstraZeneca Plc, H1 2016 63
Metastatic Melanoma - Pipeline by Basilea Pharmaceutica AG, H1 2016 64
Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 65
Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2016 66
Metastatic Melanoma - Pipeline by Bionomics Limited, H1 2016 67
Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 68
Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 69
Metastatic Melanoma - Pipeline by Cellceutix Corporation, H1 2016 70
Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 71
Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H1 2016 72
Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H1 2016 73
Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H1 2016 74
Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H1 2016 75
Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H1 2016 76
Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H1 2016 77
Metastatic Melanoma - Pipeline by Eli Lilly and Company, H1 2016 78
Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H1 2016 79
Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 80
Metastatic Melanoma - Pipeline by Galapagos NV, H1 2016 81
Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H1 2016 82
Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H1 2016 83
Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 84
Metastatic Melanoma - Pipeline by Immune Design Corp., H1 2016 85
Metastatic Melanoma - Pipeline by Immunocore Limited, H1 2016 86
Metastatic Melanoma - Pipeline by ImmuRx, Inc., H1 2016 87
Metastatic Melanoma - Pipeline by Incyte Corporation, H1 2016 88
Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 89
Metastatic Melanoma - Pipeline by IO Biotech ApS, H1 2016 90
Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2016 91
Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H1 2016 92
Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H1 2016 93
Metastatic Melanoma - Pipeline by MacroGenics, Inc., H1 2016 94
Metastatic Melanoma - Pipeline by MedImmune, LLC, H1 2016 95
Metastatic Melanoma - Pipeline by Medivation, Inc., H1 2016 96
Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H1 2016 97
Metastatic Melanoma - Pipeline by Merck & Co., Inc., H1 2016 98
Metastatic Melanoma - Pipeline by Merck KGaA, H1 2016 99
Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 100
Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H1 2016 101
Metastatic Melanoma - Pipeline by Morphotek, Inc., H1 2016 102
Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H1 2016 103
Metastatic Melanoma - Pipeline by Novartis AG, H1 2016 104
Metastatic Melanoma - Pipeline by Omeros Corporation, H1 2016 105
Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H1 2016 106
Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H1 2016 107
Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 108
Metastatic Melanoma - Pipeline by Pfizer Inc., H1 2016 109
Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H1 2016 110
Metastatic Melanoma - Pipeline by Philogen S.p.A., H1 2016 111
Metastatic Melanoma - Pipeline by Plexxikon Inc., H1 2016 112
Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 113
Metastatic Melanoma - Pipeline by Polyphor Ltd., H1 2016 114
Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H1 2016 115
Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 116
Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2016 117
Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 118
Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H1 2016 119
Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 120
Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H1 2016 121
Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 122
Metastatic Melanoma - Pipeline by Takara Bio Inc., H1 2016 123
Metastatic Melanoma - Pipeline by TC BioPharm Limited, H1 2016 124
Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H1 2016 125
Metastatic Melanoma - Pipeline by Ultimovacs AS, H1 2016 126
Assessment by Monotherapy Products, H1 2016 127
Assessment by Combination Products, H1 2016 128
Number of Products by Stage and Target, H1 2016 130
Number of Products by Stage and Mechanism of Action, H1 2016 140
Number of Products by Stage and Route of Administration, H1 2016 147
Number of Products by Stage and Molecule Type, H1 2016 149
Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H1 2016 450
Metastatic Melanoma - Dormant Projects, H1 2016 649
Metastatic Melanoma - Dormant Projects (Contd..1), H1 2016 650
Metastatic Melanoma - Dormant Projects (Contd..2), H1 2016 651
Metastatic Melanoma - Dormant Projects (Contd..3), H1 2016 652
Metastatic Melanoma - Dormant Projects (Contd..4), H1 2016 653
Metastatic Melanoma - Dormant Projects (Contd..5), H1 2016 654
Metastatic Melanoma - Dormant Projects (Contd..6), H1 2016 655
Metastatic Melanoma - Dormant Projects (Contd..7), H1 2016 656
Metastatic Melanoma - Dormant Projects (Contd..8), H1 2016 657
Metastatic Melanoma - Dormant Projects (Contd..9), H1 2016 658
Metastatic Melanoma - Dormant Projects (Contd..10), H1 2016 659
Metastatic Melanoma - Dormant Projects (Contd..11), H1 2016 660
Metastatic Melanoma - Discontinued Products, H1 2016 661
Metastatic Melanoma - Discontinued Products (Contd..1), H1 2016 662